根据计划及任何其他股份计划( 包括但不限于现有购股权计划 )将授予的所有奖励及购股权而可能发行 的股份数目上限合共不得超过采纳日期公司已发行股本的10%;而在该限额内，根据计划及任何其他股 份计划将授予服务供应商的所有奖励及购股权而可能发行的股份数目上限合共不得超过采纳日期已发行 股份总数的1 %。 计划将使公司能够透过授予奖励的方式，向合资格参与者就其对集团作出的贡献或潜在贡献提供激励， 并使彼等的利益与集团的利益保持一致。除现有购股权计划外，公司授予奖励的能力为公司提供了另一 种更贴合每位合资格参与者需求的激励方式。 智通财经APP讯，新火科技控股(01611)公布，董事会建议采纳一项符合上市规则第17章的股份奖励计 划。 ...

格隆汇9月26日丨新火科技控股(01611.HK)公告，董事会建议采纳一项符合上市规则第17章的股份奖励 计划。 根据计划及任何其他股份计划(包括但不限于现有购股权计划)将授予的所有奖励及购股权而可能发行的 股份数目上限合共不得超过采纳日期公司已发行股本的10%；而在该限额内，根据计划及任何其他股份 计划将授予服务供应商的所有奖励及购股权而可能发行的股份数目上限合共不得超过采纳日期已发行股 份总数的1%。 计划将使公司能够透过授予奖励的方式，向合资格参与者就其对集团作出的贡献或潜在贡献提供激励， 并使彼等的利益与集团的利益保持一致。除现有购股权计划外，公司授予奖励的能力为本公司提供了另 一种更贴合每位合资格参与者需求的激励方式。 ...

Core Viewpoint - The company, Canar Medical, is experiencing a decline in stock price and revenue, while benefiting from the depreciation of the RMB due to its significant overseas revenue. Group 1: Company Overview - Canar Medical specializes in the research, production, and sales of injection and puncture instruments, as well as laboratory consumables, with main products including puncture needles, syringes, laboratory consumables, and masks [2][8] - The company began supplying IVF culture tube products to Thermo Fisher in 2018 [3] - As of September 19, the number of shareholders in Canar Medical is 6,901, a decrease of 11.17% from the previous period, while the average circulating shares per person increased by 12.58% [8] Group 2: Financial Performance - For the first half of 2025, Canar Medical reported revenue of 158 million yuan, a year-on-year decrease of 18.54%, and a net profit attributable to shareholders of 9.37 million yuan, down 71.78% year-on-year [8] - The company has distributed a total of 155 million yuan in dividends since its A-share listing, with 122 million yuan distributed in the last three years [9] Group 3: Market Dynamics - The stock price of Canar Medical fell by 1.25% on September 26, with a trading volume of 48.14 million yuan and a turnover rate of 2.60%, bringing the total market value to 2.99 billion yuan [1] - The company benefits from a high overseas revenue ratio of 90.61%, which is positively impacted by the depreciation of the RMB [4] Group 4: Technical Analysis - The average trading cost of the stock is 23.47 yuan, with recent rapid outflows of shares, suggesting a recommendation for portfolio adjustment [7] - The current stock price is approaching a resistance level of 24.88 yuan, indicating potential for a pullback unless this level is broken [7]

Core Viewpoint - The company, Canar Technology Co., Ltd., has experienced a decline in stock price and financial performance, indicating potential challenges in its operations and market position [1][2]. Group 1: Stock Performance - On September 25, Canar's stock fell by 2.86%, with a trading volume of 54.56 million yuan [1]. - The margin trading data shows a net margin buy of -4.36 million yuan on the same day, with a total margin balance of 78.01 million yuan, accounting for 2.58% of the circulating market value [1]. - The margin balance is above the 90th percentile level over the past year, indicating a high level of margin trading activity [1]. Group 2: Financial Performance - For the first half of 2025, Canar reported a revenue of 158 million yuan, a year-on-year decrease of 18.54% [2]. - The net profit attributable to shareholders was 9.37 million yuan, reflecting a significant year-on-year decline of 71.78% [2]. - Since its A-share listing, Canar has distributed a total of 155 million yuan in dividends, with 122 million yuan distributed over the past three years [2]. Group 3: Company Overview - Canar Technology Co., Ltd. was established on July 23, 2004, and went public on January 26, 2022 [1]. - The company's main business involves the research, production, and sales of medical and veterinary injection and puncture instruments, as well as laboratory consumables [1]. - The revenue composition includes 45.17% from syringes, 45.01% from puncture needles, 5.49% from laboratory consumables, and 4.33% from other sources [1].

Investment Rating - The report recommends focusing on leading companies in various segments of the high-value consumables and medical device sectors, indicating a positive outlook for recovery and growth in these areas [4][30]. Core Insights - High-value consumables have begun to recover from the impacts of centralized procurement, with leading companies regaining profitability levels seen before the procurement initiatives [4][32]. - The medical device and IVD sectors are expected to show signs of recovery, with significant improvements anticipated in financial performance by Q3 2025 for device companies and by Q4 2025 for IVD companies [4][30]. - The report highlights specific high-growth segments, including vascular intervention, orthopedics, and IVD, suggesting that these areas will continue to attract investment due to their growth potential and market dynamics [4][30]. Summary by Sections Medical Devices - The medical device sector is projected to experience a revenue decline in 2024, with a further drop of -5.18% expected in the first half of 2025, but recovery is anticipated thereafter [9][12]. - Despite revenue challenges, the overall gross margin and net profit margin have remained stable, with R&D expenses increasing from approximately 7% pre-pandemic to around 10% currently [10][12]. - Companies in the imaging equipment segment are expected to see improved performance in Q3 2025 as inventory issues are resolved and new procurement projects are executed [13][18]. High-Value Consumables - The high-value consumables sector has shown revenue growth in the first half of 2025, indicating a recovery from previous declines, with profit margins returning to levels seen in 2021 [32][33]. - Specific segments such as vascular intervention and orthopedics are highlighted for their resilience and growth potential, with companies like Huatai Medical and Weigao Orthopedics showing significant revenue increases [38][43]. IVD and Other Segments - The IVD sector is expected to see improvements by Q4 2025, with overall industry recovery projected for the first half of 2026 [4][30]. - The report emphasizes the importance of innovation and market expansion for companies in the rehabilitation and home medical device sectors, with firms like Sanofi and Kefu Medical showing strong growth despite market challenges [24][26].

证券日报网讯采纳股份9月22日在互动平台回答投资者提问时表示，截至2025年9月19日，在中国证券登 记结算有限责任公司深圳分公司登记在册的公司股东数为6901户。 （文章来源：证券日报） ...

Group 1 - Honghe Technology plans to increase capital by 300 million yuan to its wholly-owned subsidiary Huangshi Honghe through debt-to-equity conversion, raising its registered capital from 700 million yuan to 1 billion yuan [1] - Huaxia Happiness has completed debt restructuring amounting to approximately 192.67 billion yuan, with a total of 24 billion yuan in overdue debts as of August 31 [1] - Chengyi Pharmaceutical's controlling shareholder plans to reduce its stake by up to 1.18%, amounting to 387,560 shares [1][2] Group 2 - Yuanwang Valley received a warning letter from the Shenzhen Securities Regulatory Bureau for failing to halt trading when its controlling shareholder's stake changed to a multiple of 5% [2] - Gongjin Co. received government subsidies of 8.9 million yuan, accounting for 11.13% of its latest audited net profit [3] - Maiwei Biotech's application for the listing of 9MW0813 injection has been accepted by the National Medical Products Administration [4] Group 3 - Jianfeng Group plans to repurchase shares worth between 20 million and 40 million yuan at a maximum price of 12.42 yuan per share [6] - Ankai Micro plans to invest 20 million yuan to acquire a 4% stake in Shiqi Future [7] - Pinming Technology's stock will continue to be suspended as it is actively pursuing a significant matter that may lead to a change in control [8] Group 4 - China Communications has signed new contracts worth 256.34 billion yuan from January to August, with domestic contracts totaling 206.05 billion yuan [18] - Round Express reported a revenue of 5.39 billion yuan in August, a year-on-year increase of 9.82% [38] - China Pacific Insurance's original insurance premium income reached 217.05 billion yuan from January to August, up 13.2% year-on-year [39] Group 5 - *ST Chuangxing's chairman is under investigation, and the general manager will act as the chairman during this period [40] - Fengshan Group signed a technical development contract with Tsinghua University for a project related to sodium-ion battery electrolytes [40] - Yongxin Optical stated that its optical components related to lithography machines account for less than 1% of its revenue [41] Group 6 - Tianyuan Dike's subsidiary received a government subsidy of 3.77 million yuan, representing 16.27% of its latest audited net profit [42] - Huaxiang Co. plans to issue convertible bonds to raise no more than 1.308 billion yuan for various projects [43] - Wolong Electric Drive reported that its robot-related products accounted for only 2.71% of total revenue in the first half of the year [44]

证券代码：301122 证券简称：采纳股份 公告编号：2025-083 采纳科技股份有限公司 关于使用部分闲置自有资金进行现金管理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 采纳科技股份有限公司（以下简称"公司"）召开的第三届董事会第十二次 会议、第三届监事会第十一次会议、2025 年第一次临时股东大会，分别审议通 过了《关于使用部分闲置募集资金和自有资金进行现金管理的议案》，同意公司 及全资子公司在确保不影响募集资金投资项目和公司正常经营，并有效控制风险 的前提下，使用额度不超过人民币 20,000 万元（含本数）的闲置募集资金（含 超募资金）和额度不超过人民币 80,000 万元（含本数）的自有资金进行现金管 理。使用期限自股东大会审议通过之日起 12 个月内有效。在上述额度和期限内， 资金可循环滚动使用。 同时，在额度范围内授权公司管理层行使相关投资决策权并签署相关文件， 具 体 由 公 司 财 务 部 负 责 组 织 实 施 。 具 体 内 容 详 见 公 司 在 巨 潮 资 讯 网 （www.cninfo.com.cn）披露的相关公告。 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and stock trading activities of Canar Technology Co., Ltd. as of mid-September 2023 [1][2] - As of September 15, 2023, Canar's stock price increased by 1.28%, with a trading volume of 97.68 million yuan [1] - The financing buy-in amount for Canar on September 15 was 14.09 million yuan, while the financing repayment was 9.35 million yuan, resulting in a net financing buy-in of 4.74 million yuan [1] - The total financing and securities lending balance for Canar reached 70.95 million yuan, accounting for 2.30% of its market capitalization, indicating a high level compared to the past year [1] - The company has a significant reliance on its main business segments, with revenue contributions of 45.17% from syringes, 45.01% from puncture needles, 5.49% from laboratory consumables, and 4.33% from other products [1] Group 2 - As of September 10, 2023, the number of shareholders for Canar increased by 4.82% to 7,769, while the average circulating shares per person decreased by 4.60% to 9,736 shares [2] - For the first half of 2025, Canar reported an operating income of 158 million yuan, a year-on-year decrease of 18.54%, and a net profit attributable to shareholders of 9.37 million yuan, down 71.78% year-on-year [2] - Since its A-share listing, Canar has distributed a total of 155 million yuan in dividends, with 122 million yuan distributed over the past three years [2]

Group 1 - The company, Cai Na Co., Ltd. (301122), reported that as of September 10, 2025, the number of registered shareholders at the Shenzhen branch of China Securities Depository and Clearing Co., Ltd. is 7,769 [1]